These are the factors that typically point toward the slower path: Prior intolerable nausea or vomiting on semaglutide, tirzepatide, or other GLP-1 medications History of GERD, gastroparesis, or functional GI disorders Lower body weight, where the effective dose-per-kilogram is relatively higher at standard doses First-time users of peptide or GLP-class medications with no tolerability baseline The slow-titration approach does not change the target dose or the expected outcomes
GLP-1 receptor agonists (GLP-1 RAs) mimic glucagon-like peptide-1, a hormone released from the gut after eating
Aerobic activity Walking, cycling, swimming, and gentle jogging are all good options
Lain KY, Catalano PM (2007)
it is only FDA-approved for diabetes treatment
The room temperature peptide stability guide outlines exactly how long unreconstituted peptides remain viable outside the fridge